R M Myers, S M Greiner, M E Harvey, G Griesmann, M J Kuffel, S A Buhrow, J M Reid, M Federspiel, M M Ames, D Dingli, K Schweikart, A Welch, A Dispenzieri, K-W Peng, S J Russell
MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol "Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma." Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 x 10(6) TCID50 (tissue culture infectious dose 50)/kg...
December 2007: Clinical Pharmacology and Therapeutics